HCG 5000iu

Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone (MW: 36,700 Da) composed of two subunits (α: 92 aa, β: 145 aa) joined non-covalently. Naturally produced by the placental syncytiotrophoblast during pregnancy, hCG exhibits biological activity analogous to pituitary LH (luteinizing hormone) with greater potency and an extended half-life.

Molecular Structure:

• Alpha subunit Identical to LH, FSH, TSH (common)
• Beta subunit: Specific hCG (confers biological specificity)
• Glycosylation: 30% molecular weight (4 N-glycosylation sites, 4 O-glycosylation sites)
• Half-life: 24–36 hours (vs. 20 min LH, due to hyperglycosylation)

Mechanisms of Action:

1. LH/hCG Receptor Activation (LHCGR):

• Receptor: GPCR (7-transmembrane) in testicular Leydig cells, ovarian theca
• Translation: Gs protein coupling → adenylate cyclase → ↑ cAMP → PKA
• Cascade: StAR (steroidogenic acute regulatory protein) phosphorylation
• Result: Mitochondrial cholesterol transport → steroidogenesis

2. Testicular Steroidogenesis:

• Leydig cells: testosterone synthesis stimulation
• Key enzymes: CYP11A1 (side-chain cleavage), 3β-HSD, 17β-HSD
• Testosterone production: 200–400% increase in baseline levels
• Paracrine effects: spermatogenesis support (Sertoli cells)

3. Ovarian Function

• Preovulatory follicle: final maturation, ovulation
• Corpus luteum: maintenance of progesterone production
• Luteinization: granulosa/theca cell differentiation
• Angiogenesis: luteal body vascularization (VEGF pathway)

Recombinant hCG Pharmacokinetics:

• SC bioavailability: 40–50% (vs. 100% IM)
• IM bioavailability: ~100%
• Tmax: 12-24 hours (SC), 6-12 hours (IM)
• Half-life: 29-36 hours (allows for 2-3x/week dosing)
• Renal clearance: primary
• Detection: urine/serum up to 7-14 days post-administration

1. MALE FERTILITY AND SPERMATOGENESIS

Hypogonadotropic Hypogonadism:

Steroidogenesis Restoration

• Serum testosterone: increase from <100 ng/dL to 400-700 ng/dL
• Response time: detectable levels 48-72h, normalization 2-4 weeks
• Typical research dose: 500-2500 IU 2-3x/week
• Maintenance: reduced dose after normalization

Spermatogenesis Induction

• Combination: hCG + hMG (FSH-like) or hCG + recombinant FSH
• Sperm concentration: increase from azoospermia to 5-15 million/mL (12-24 months)
• Motility: improvement 30-40%
• Prolonged treatment: 18-24 months typical for complete spermatogenesis

Cryptorchidism (Animal Models):

• Testicular descent: gubernaculum stimulation
• Success rate: 20-40% spontaneous reduction (pre-surgical)
• Protocol: 250-1000 IU 2x/week, 4-6 weeks
• Mechanism: androgens + insulin-like factor 3 (INSL3)

2. PREVENTION OF TESTICULAR ATROPHY DURING GONADAL SUPPRESSION

Androgen Suppression Models

Use of Exogenous Androgens (Research):

• Negative feedback: exogenous testosterone → LH/FSH suppression → testicular atrophy
• Preventive hCG: maintains intratesticular Leydig cell stimulation
• Testicular volume: preservation 70–851 TP3T vs. 40–601 TP3T without hCG
• Intratesticular testosterone: maintenance of high local levels (spermatogenesis)

Preventive Protocols

• Dosage: 250-500 IU 2x/week during suppression
• Timing: simultaneous onset with exogenous androgens
• Recovery: Reduced post-cycle recovery time 50%

3. BODY WEIGHT AND COMPOSITION (CONTROVERSIAL)

Simeons Protocol (Historical):

Original Concept (1954):

• hCG 125-200 IU/day + 500 cal/day diet
• Hypothesis: hCG mobilizes “abnormal” fat without hunger
• Weight loss: 0.5-1 lb/day reported

Modern Scientific Evidence:

• Meta-analysis (Lijesen et al., 1995): No significant difference vs placebo
• Weight loss: attributable to severe caloric restriction, not hCG
• Hunger: validated reduction vs. placebo
• Lean mass: significant loss (negative effect)

Conclusion Consensus:

• hCG for weight loss No robust scientific evidence
• FDA (1975): “Not effective for obesity” labeling”
• Research use: focus on reproductive/endocrine mechanisms

4. DIAGNOSIS AND TESTING LEYDIG CELL FUNCTION

hCG Stimulation Test:

Diagnostic Protocol:

• Basal: testosterone, LH, FSH
• Administration: 1500-5000 IU hCG single IM dose
• Post-stimulation: testosterone 72-96h after
• Interpretation
  • Normal response: ↑ testosterone >200 ng/dL above baseline
  • Primary failure: no response (Leydig cell damage)
  • Secondary failure: present response but low baseline

Applications:

• Differentiation between primary and secondary hypogonadism
• Pre-pubertal Leydig cell reserve evaluation
• Treatment response prediction

5. OVULATION INDUCTION (Female Models)

Assisted Reproductive Technologies

Ovulatory Trigger

• Timing: Administration when dominant follicle ≥18-20mm
• Dosage: 5,000-10,000 IU single dose
• Ovulation: 34-36 hours post-administration
• Mechanism: mimics natural LH surge

Luteal Phase Support

• Dosage: 1500-2500 IU every 3-4 days
• Duration: 2 weeks post-ovulation

• Maintenance: corpus luteum progesterone production
• Alternative: exogenous progesterone (most common clinically)

Controlled Superovulation

• Combination: FSH + hCG final maturation
• Models: IVF, assisted reproduction research
• Multiple follicles: synchronized development
• Precise timing: oocyte retrieval 34-36h post-hCG

Dosage Male Models

Rodents (Rats/Mice):

Non-Human Primates

Female Model Dosages

Rodents:

Rabbits/Primates:

In Vitro Studies

Primary Leydig Cells

• Concentration: 0.1-10 IU/mL (typically 1 IU/mL)
• Steroidogenesis: testosterone measurement ELISA 24-48h
• Gene expression: StAR, CYP11A1, 3β-HSD (RT-qPCR)
• Viability: MTT, apoptosis (Annexin V)
• Signaling: Intracellular cAMP (ELISA/Radioimmunoassay)

Granulosa cells

• Concentration: 1-10 IU/mL
• Luteinization: progesterone production
• Receptor expression: LHCGR, FSHR
• Proliferation: BrdU incorporation

Testicular Explants:

• Organotypic culture: immature testicular tissue
• hCG: 0.5-5 IU/mL medium culture
• Maturation: seminiferous tubule development
• Spermatogenesis: Histological Analysis

hCG Preparation (Typically Lyophilized):

1. Sales Presentation
   • Lyophilized vial + diluent (bacteriostatic water or saline)
   • Common concentrations: 5,000 IU, 10,000 IU per vial
2. Reconstitution Protocol:
   • Clean the stoppers on both vials with 70% alcohol
   • Add diluent to the lyophilized hCG vial:
     • 5,000 units 5mL → 1,000 IU/mL
     • 10,000 IU 10mL → 1,000 IU/mL
   • Slowly inject through the vial wall
   • Gently swirl (DO NOT shake vigorously)
   • Dissolving: 1-2 minutes, clear solution
3. Verification:
   • Clear, colorless solution
   • Without particles or precipitate
   • Discard if cloudy

Storage:

Administration Routes

• Intramuscular (IM) First choice, optimal bioavailability
• Subcutaneous (SC) Acceptable, bioavailability ~40–50% IM

Intraperitoneal (IP): Small rodents, preclinical research

hCG vs. TRT (Testosterone Replacement Therapy) for Hypogonadism R: Critical differences:

hCG

• Intratesticular testosterone: maintained (spermatogenesis preserved)
• Testicular volume: preserved
• Fertility: maintained/restorable
• Frequency: 2-3x/week
• Cost: higher

TRT

• Intratesticular testosterone: suppressed (atrophy, infertility)
• Testicular volume: reduced 30-50%
• Fertility: compromised
• Frequency: variable (daily-weekly depending on formulation)
• Cost: lower

Choice: hCG if fertility/testicular function is important; TRT if only androgen replacement.

Q: hCG + FSH combination protocol for spermatogenesis? Standard protocol for hypogonadotropic hypogonadism:

• hCG 1500-2500 IU, 2-3x/week (Leydig/testosterone stimulation)
• Recombinant FSH 75-150 IU, 3x/week (direct spermatogenesis)
• Duration: 12-24 months typically
• Monitoring Seminal analysis every 3 months, testosterone monthly
• Success rate: Detectable sperm in 60–80% cases

LH/hCG receptor desensitization? Possible with high doses or excessive frequency:

• Downregulation Chronic high exposure → reduction LHCGR expression
• Prevention Physiological doses (500-1500 IU 2-3x/week)
• Signs Decreased testosterone response, requires increasing doses
• Recovery Rest 4-8 weeks to restore sensitivity

Main side effects research? Dose-dependent effects:

• Leaves: Injection site pain, fluid retention, acne
• Moderates Gynecomastia (testosterone aromatization→estradiol)

Rare: Hyper